CAR-T Cell Therapies in Refractory RMD Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare. Recent anecdotal reports suggest that CD19-directed CAR-T cell therapy may https://t.co/lXX5RjEw6a

JAK Safety Debate Continues: Stronger VTE signal, less clear cancer signal Few topics in rheumatology have reshaped prescribing behavior as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings. Even https://t.co/wfQZn1hO3N

Getting #RA and IA diagnosed faster: UK RheumACaN program (integrated education + pathway redesign) ↑ clinician confidence 4.4 to 8.6/10. Referral within 3 days: 52% → 70%, with sustained improvement. Education that translates to real outcomes. @RheumNow #EULAR2026 POS0784 https://t.co/1Va9rkLBHM

#EULAR2026 OP0220 How can we improve physical function of #SLE patients? Cross-sectional study of 2 US cohorts: poor physical function was associated with Fatigue, depression, learned helplessness and perceived stress. We should focus on improving fatigue & wellbeing @RheumNow https://t.co/vAFqYyuzgN

Proud to present POS0784 at #EULAR2026. RheumACaN education + pathway redesign across primary and secondary care improved early inflammatory arthritis referrals within 3 working days from 52% to 70%, exceeding the national benchmark. 95% of clinicians changed their practice. https://t.co/W6VViVRndp

EULAR 2026 Daily Recap LIVE By Day 3, the biggest stories of EULAR begin to emerge. Join Dr. Jack Cush and https://t.co/V10S4oVFsv faculty for a fast-paced review of the studies, debates, and breakthrough findings that rheumatologists will be discussing long after the meeting https://t.co/7hvwCkUz9C

⏰ The question rheumatologists keep asking: Does early axSpA diagnosis reduce long-term spinal damage? Answer from the SCQM registry (n=376): Early diagnosis linked to 3.85 fewer mSASSS points long-term, esp. in HLA-B27+ males #POS0191 #EULAR2026 @RheumNow https://t.co/HM5kvqXMEh

📋 Do 2025 ASAS-SPARTAN criteria classify fewer real-world axSpA patients? Data from the RABBIT-SpA registry (n=2,236) confirms: 67% vs 73% with 2009 criteria Clinical arm rarely fulfilled #POS0190 #EULAR2026 @RheumNow https://t.co/HYie4w8c6r

🔍 Do posterior element lesions progress over 10 years in axSpA? Data from the DESIR inception cohort (n=320) says RARELY! But baseline PE inflammation raises facet ankylosis risk ~70-fold #POS0189 #EULAR2026 @RheumNow https://t.co/PdwlPGjKqK

🔮 Can polygenic risk scores predict PsA timing in psoriasis? Another GWAS study (n=703) says YES! 70-SNP model achieves AUC 0.843 for predicting PsA onset <10 vs >10 years #POS0088 #EULAR2026 @RheumNow https://t.co/wI4Jy8Yu2A

From Skepticism to Reconsideration: 4‑Year CAR‑T Outcomes in Lupus Chimeric antigen receptor (CAR) T‑cell therapy, long established in hematologic malignancies, is now emerging as a transformative approach in systemic lupus erythematosus (SLE), a disease historically managed https://t.co/Dmmw90XnuF